2021
DOI: 10.1245/s10434-021-10860-y
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
24
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(24 citation statements)
references
References 36 publications
0
24
0
Order By: Relevance
“…They detected a major or complete response in 33% and 22% of the patients at the third PIPAC, while none and 3%, respectively, had no response to treatment [ 53 ]. In a retrospective study on patients with gastric cancer, baseline PRGS were not available, but a major or complete response was seen in 27 (19%) and a minor or no response in 9 (6%) patients at the third PIPAC [ 54 ]. The authors concluded that the completion of more than two PIPACs had prognostic value, while PRGS did not.…”
Section: Resultsmentioning
confidence: 99%
“…They detected a major or complete response in 33% and 22% of the patients at the third PIPAC, while none and 3%, respectively, had no response to treatment [ 53 ]. In a retrospective study on patients with gastric cancer, baseline PRGS were not available, but a major or complete response was seen in 27 (19%) and a minor or no response in 9 (6%) patients at the third PIPAC [ 54 ]. The authors concluded that the completion of more than two PIPACs had prognostic value, while PRGS did not.…”
Section: Resultsmentioning
confidence: 99%
“…The technique is safe and potentially cost-effective ( 73 , 74 ). Early survival estimates from small trials of PIPAC plus chemotherapy have shown efficacy in comparison to chemotherapy alone ( 75 ), as well as responses conferring eligibility for CRS-HIPEC trials ( 76 ). Larger-scale trials are underway ( 71 , 77 ).…”
Section: Future Directionsmentioning
confidence: 99%
“…However, the majority will have extensive disease that prevents this strategy. 1 A theory that tries to explain the poor prognosis and the lack of a valid therapeutic option for PM is called the 'plasmaperitoneal barrier'. 2 This phenomenon is similar to the blood-brain barrier, in which the diffusion of systemic drugs is limited.…”
mentioning
confidence: 99%
“…However, in patients with good response, the number of sessions can be extended. 1 Due to the selection bias and lack of randomized trials, it is impossible to properly appraise the survival benefits of this approach. However, the results have been encouraging, with an objective tumor response according to the histological Peritoneal Regression Grading Score of around 70% 4 and, in some patients, with a reduction in PM that allows subsequent cytoreduction surgery and HIPEC.…”
mentioning
confidence: 99%